PARP (Poly ADP-ribose Polymerase) Inhibitors Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : August 2019 Pages : 140 Category: Pharma & Healthcare Report Code : HC085033
PARP (Poly ADP-ribose Polymerase) Inhibitors Market by Type (Talazoparib, Olaparib) Application (Breast Cancer, Ovarian Cancer, Other) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The PARP (Poly ADP-ribose Polymerase) Inhibitors Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. PARP inhibitors are a section of pharmacological inhibitors of the compound polymerase ADP ribosome (PARP).They are produced for numerous indications. PARP inhibitors can upgrade the adequacy of radiotherapy, alkalization specialists and platinum-based chemotherapy by hindering DNA harm fix and advancing apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors are extremely successful in treating strong tumors and other diseases. Such as cutting edge ovarian malignant growth, fallopian tube malignancy and essential peritoneal cancer.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Power Tools market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Everest Pharmaceuticals
- Pfizer
- AbbVie
- AstraZeneca
- Clovis Oncology
- GlaxoSmithKline
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Talazoparib
o Olaparib
o PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Breast Cancer
o Ovarian Cancer
o Other
o PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Everest Pharmaceuticals
o Pfizer
o AbbVie
o AstraZeneca
o Clovis Oncology
o GlaxoSmithKline
o PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market , By Country
o U.S. PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Europe
§ Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market , By Country
o Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o UK PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o France PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Asia-Pacific
§ Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market , By Country
o China PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o South Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o India PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o South America
§ South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market , By Country
o Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Middle East and Africa
§ Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market , By Country
o Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o UAE PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market
o Rest of MEA PARP (Poly ADP-ribose Polymerase) Inhibitors Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Type
5.1. Introduction
5.2. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Market Share by Type (2017-2027)
5.2.1. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Revenue Share by Type (2017-2027)
5.3. Talazoparib
5.3.1. Global Talazoparib Revenue and Growth Rate (2017-2027)
5.4. Olaparib
5.4.1. Global Olaparib Revenue and Growth Rate (2017-2027)
6. PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Application
6.1. Introduction
6.2. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Market Share by Application (2017-2027)
6.2.1. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Revenue Share by Application (2017-2027)
6.3. Breast Cancer
6.3.1. Global Breast Cancer Revenue and Growth Rate (2017-2027)
6.4. Ovarian Cancer
6.4.1. Global Ovarian Cancer Revenue and Growth Rate (2017-2027)
6.5. Other
6.5.1. Global Other Revenue and Growth Rate (2017-2027)
7. PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Region
7.1. Introduction
7.2. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Market Share by Regions
7.2.1. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by Regions (2017-2027)
7.3. North America PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries
7.3.1. North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2027)
7.3.2. North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries
7.4.1. Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2027)
7.4.2. Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries
7.5.1. Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries
7.6.1. South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2027)
7.6.2. South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries
7.7.1. Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Everest Pharmaceuticals
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Pfizer
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. AbbVie
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. AstraZeneca
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Clovis Oncology
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. GlaxoSmithKline
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
9. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.1. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast by Regions (2017-2027)
9.2.1. North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.1.1. United States PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.1.2. Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.1.3. Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2. Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2.1. Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2.2. France PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2.3. UK PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2.4. Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2.5. Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.2.6. Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3. Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3.1. China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3.2. Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3.3. Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3.4. India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3.5. Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.4. South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.4.1. Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.4.2. Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.4.3. Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.4.4. Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5. Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.3. Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.4. Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.5. South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.6. Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2017-2027)
9.3. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast by Type (2017-2027)
9.3.1. PARP (Poly ADP-ribose Polymerase) Inhibitors Forecast by Type (2017-2027)
9.3.2. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share Forecast by Type (2017-2027)
9.4. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast by Application (2017-2027)
9.4.1. PARP (Poly ADP-ribose Polymerase) Inhibitors Forecast by Application (2017-2027)
9.4.2. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure France PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure China PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure India PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) and Growth Rate (2017-2025)
Table Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Revenue Share by Type (2017-2018)
Figure Global Talazoparib Revenue and Growth Rate (2017-2018)
Figure Global Olaparib Revenue and Growth Rate (2017-2018)
Table Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Revenue Share by Application (2017-2018)
Figure Global Breast Cancer Revenue and Growth Rate (2017-2018)
Figure Global Ovarian Cancer Revenue and Growth Rate (2017-2018)
Figure Global Other Revenue and Growth Rate (2017-2018)
Table Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by Regions (2017-2018)
Figure North America PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2018)
Figure North America PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries (2017-2018)
Figure North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2018)
Figure United States PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure United States PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2018)
Figure Europe PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries (2017-2018)
Figure Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2018)
Figure Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure France PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure UK PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries (2017-2018)
Figure Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2018)
Figure China PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure China PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure India PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2018)
Figure South America PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries (2017-2018)
Figure South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2018)
Figure Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors by Countries (2017-2018)
Figure Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure United Arab Emirates PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Rate (2017-2018)
Figure Rest of Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2017-2018)
Table Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Financial Overview
Table Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Financial Overview
Table AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Financial Overview
Table AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Financial Overview
Table Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Financial Overview
Table GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Financial Overview
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (Millions USD) and Growth Rate (2018-2025)
Table PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast by Regions (2018-2025)
Figure North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure United States PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure France PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure UK PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Rest of Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Rest of Asia-Pacific PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Columbia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Rest of South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure United Arab Emirates PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Egypt PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Nigeria PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure South Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Rest of Middle East and Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Market Forecast (2018-2025)
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Forecast by Type (2018-2025)
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share Forecast by Type (2018-2025)
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Forecast by Type (2018-2025)
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Forecast by Application (2018-2025)
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share Forecast by Application (2018-2025)
Figure Global PARP (Poly ADP-ribose Polymerase) Inhibitors Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|